Altimmune (ALT) Accumulated Depreciation (2016 - 2025)

Altimmune (ALT) has 10 years of Accumulated Depreciation data on file, last reported at $2.3 million in Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 5.06% year-over-year to $2.3 million in Q4 2025; TTM through Dec 2025 was $2.3 million, a 5.06% increase from a year earlier, with the FY2025 full-year figure at $2.3 million, up 5.06% from the prior year.
• Accumulated Depreciation for Q4 2025 stood at $2.3 million, up from $2.2 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for ALT reached as high as $2.3 million in Q4 2025 and fell as low as $1.1 million in Q1 2022.
• Historically, Accumulated Depreciation has averaged $1.9 million across 5 years, with a median of $1.9 million in 2021.
• Across the five-year window, Accumulated Depreciation plunged 36.08% in 2022 and jumped 31.84% in 2023, its largest moves.
• Year by year, Accumulated Depreciation stood at $2.0 million in 2021, then declined by 26.82% to $1.5 million in 2022, then surged by 31.84% to $2.0 million in 2023, then grew by 12.05% to $2.2 million in 2024, then gained by 5.06% to $2.3 million in 2025.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $2.3 million in Q4 2025, $2.2 million in Q4 2024, and $2.0 million in Q4 2023.